Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan

Yen Ying Lee, Paul Hsiao, You Meei Lin, Yu Hsuan Yen, Hsiang Yin Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Therapeutic interchange is not a common practice in the medical society in Asia. We used clinic blood pressure readings, patients' tolerance, and cost saving as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan. Methods: Taipei Medical University-Wan Fang Hospital initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic efficacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation. Results: Patients whose treatment was converted to candesartan experienced no statistically significant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied. Only 3.15% of the patients developed adverse drug reactions potentially related to candesartan, and none required hospitalization. Conclusions: Based on the results of this retrospective chart review, the present ARB therapeutic interchange program was successfully developed and implemented. This is the first study to establish the positive impact of a well-run ARB therapeutic interchange program in Taiwan.

Original languageEnglish
JournalValue in Health
Volume15
Issue number1 SUPPL.
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Angiotensin Receptor Antagonists
Taiwan
Therapeutics
Blood Pressure
Drug Costs
Cost Savings
Medical Societies
Drug-Related Side Effects and Adverse Reactions
Antihypertensive Agents
Reading
Hospitalization
Outpatients
Costs and Cost Analysis

Keywords

  • angiotensin II receptor blockers
  • candesartan
  • hypertension
  • therapeutic interchange

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan. / Lee, Yen Ying; Hsiao, Paul; Lin, You Meei; Yen, Yu Hsuan; Chen, Hsiang Yin.

In: Value in Health, Vol. 15, No. 1 SUPPL., 01.2012.

Research output: Contribution to journalArticle

@article{72874d5f95fe4c7382c49a0cdb530346,
title = "Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan",
abstract = "Objective: Therapeutic interchange is not a common practice in the medical society in Asia. We used clinic blood pressure readings, patients' tolerance, and cost saving as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan. Methods: Taipei Medical University-Wan Fang Hospital initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic efficacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation. Results: Patients whose treatment was converted to candesartan experienced no statistically significant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied. Only 3.15{\%} of the patients developed adverse drug reactions potentially related to candesartan, and none required hospitalization. Conclusions: Based on the results of this retrospective chart review, the present ARB therapeutic interchange program was successfully developed and implemented. This is the first study to establish the positive impact of a well-run ARB therapeutic interchange program in Taiwan.",
keywords = "angiotensin II receptor blockers, candesartan, hypertension, therapeutic interchange",
author = "Lee, {Yen Ying} and Paul Hsiao and Lin, {You Meei} and Yen, {Yu Hsuan} and Chen, {Hsiang Yin}",
year = "2012",
month = "1",
doi = "10.1016/j.jval.2011.11.001",
language = "English",
volume = "15",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan

AU - Lee, Yen Ying

AU - Hsiao, Paul

AU - Lin, You Meei

AU - Yen, Yu Hsuan

AU - Chen, Hsiang Yin

PY - 2012/1

Y1 - 2012/1

N2 - Objective: Therapeutic interchange is not a common practice in the medical society in Asia. We used clinic blood pressure readings, patients' tolerance, and cost saving as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan. Methods: Taipei Medical University-Wan Fang Hospital initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic efficacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation. Results: Patients whose treatment was converted to candesartan experienced no statistically significant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied. Only 3.15% of the patients developed adverse drug reactions potentially related to candesartan, and none required hospitalization. Conclusions: Based on the results of this retrospective chart review, the present ARB therapeutic interchange program was successfully developed and implemented. This is the first study to establish the positive impact of a well-run ARB therapeutic interchange program in Taiwan.

AB - Objective: Therapeutic interchange is not a common practice in the medical society in Asia. We used clinic blood pressure readings, patients' tolerance, and cost saving as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan. Methods: Taipei Medical University-Wan Fang Hospital initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic efficacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation. Results: Patients whose treatment was converted to candesartan experienced no statistically significant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied. Only 3.15% of the patients developed adverse drug reactions potentially related to candesartan, and none required hospitalization. Conclusions: Based on the results of this retrospective chart review, the present ARB therapeutic interchange program was successfully developed and implemented. This is the first study to establish the positive impact of a well-run ARB therapeutic interchange program in Taiwan.

KW - angiotensin II receptor blockers

KW - candesartan

KW - hypertension

KW - therapeutic interchange

UR - http://www.scopus.com/inward/record.url?scp=84862943507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862943507&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2011.11.001

DO - 10.1016/j.jval.2011.11.001

M3 - Article

C2 - 22265056

AN - SCOPUS:84862943507

VL - 15

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 1 SUPPL.

ER -